|Mr. Jesper Høiland||Pres, CEO & Director||1.05M||N/A||1960|
|Mr. Jose Carmona||CFO, Sr. VP & Treasurer||673.46k||N/A||1972|
|Mr. Joseph Kelly||Sr. VP of Sales & Marketing||654.33k||N/A||1969|
|Dr. Charles Q. Morris||Chief Medical Officer||414.09k||N/A||1965|
|Dr. Stavros C. Manolagas||Co-Founder & Member of the Scientific Advisory Board||N/A||N/A||N/A|
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Radius Health, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 9.